APO-2 is under clinical development by Aposcience and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect APO-2’s likelihood of approval (LoA) and phase transition for Diabetic Foot Ulcers took place on 26 Oct 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their APO-2 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

APO-2 overview

APO-2 is under development for the treatment of diabetic foot ulcer, contact dermatitis and other chronic dermal wounds. The drug candidate is administered through a cutaneous and topical routes. It is comprised of apoptotic peripheral blood mononuclear cells (APOSEC). These apoptotic cells are derived from peripheral blood mononuclear cells (PBMCs). The drug candidate acts by targeting cytoprotective kinase pathways involved in wound healing.

Quick View APO-2 LOA Data

Report Segments
  • Innovator
Drug Name
  • APO-2
Administration Pathway
  • Cutaneous
  • Topical
Therapeutic Areas
  • Dermatology
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.